Sweep­ing re­org at Ori­on — cen­tered around can­cer and pain — claims 30 staffers

More than a month af­ter Ori­on sig­naled that it’s go­ing to bring out the bud­get axe in search of a ma­jor shift, the Bay­er part­ner has set­tled on a plan — and fi­nal­ized how deep the cuts are go­ing to be.

The Finnish biotech has de­cid­ed to fo­cus on can­cer and pain mov­ing for­ward while mov­ing out of neu­rode­gen­er­a­tive and rare dis­eases. In ad­di­tion, it’s drop­ping the de­vel­op­ment of a chron­ic ob­struc­tive pul­monary dis­ease treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER